Stock Analysis on Net

IQVIA Holdings Inc. (NYSE:IQV)

This company has been moved to the archive! The financial data has not been updated since November 1, 2023.

Analysis of Long-term (Investment) Activity Ratios 

Microsoft Excel

Long-term Activity Ratios (Summary)

IQVIA Holdings Inc., long-term (investment) activity ratios

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net fixed asset turnover 18.94 20.31 18.81 24.21 23.99
Net fixed asset turnover (including operating lease, right-of-use asset) 13.20 12.74 10.57 11.62 23.99
Total asset turnover 0.57 0.56 0.46 0.48 0.46
Equity turnover 2.50 2.30 1.89 1.85 1.55

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. IQVIA Holdings Inc. net fixed asset turnover ratio improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022 not reaching 2020 level.
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). IQVIA Holdings Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from 2020 to 2021 and from 2021 to 2022.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. IQVIA Holdings Inc. total asset turnover ratio improved from 2020 to 2021 and from 2021 to 2022.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. IQVIA Holdings Inc. equity turnover ratio improved from 2020 to 2021 and from 2021 to 2022.

Net Fixed Asset Turnover

IQVIA Holdings Inc., net fixed asset turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Revenues 14,410 13,874 11,359 11,088 10,412
Property and equipment, net, including finance lease right-of-use assets 761 683 604 458 434
Long-term Activity Ratio
Net fixed asset turnover1 18.94 20.31 18.81 24.21 23.99
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc. 11.76 11.00 8.73 11.23
Amgen Inc. 4.57 4.69 4.96 4.51
Bristol-Myers Squibb Co. 7.38 7.67 7.22 4.18
Danaher Corp. 7.96 7.77 6.83 7.78
Eli Lilly & Co. 2.81 3.15 2.83 2.83
Gilead Sciences Inc. 4.93 5.27 4.90 4.91
Johnson & Johnson 4.79 4.95 4.40 4.65
Merck & Co. Inc. 2.77 2.53 2.67 3.11
Moderna Inc. 9.14 14.24 0.67 0.00
Pfizer Inc. 6.17 5.46 3.01 3.71
Regeneron Pharmaceuticals Inc. 3.23 4.62 2.64 2.72
Thermo Fisher Scientific Inc. 4.84 4.71 5.45 5.38
Net Fixed Asset Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 5.02 5.06 4.27 4.30
Net Fixed Asset Turnover, Industry
Health Care 10.62 10.44 9.62 9.73

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Net fixed asset turnover = Revenues ÷ Property and equipment, net, including finance lease right-of-use assets
= 14,410 ÷ 761 = 18.94

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. IQVIA Holdings Inc. net fixed asset turnover ratio improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022 not reaching 2020 level.

Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)

IQVIA Holdings Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Revenues 14,410 13,874 11,359 11,088 10,412
 
Property and equipment, net, including finance lease right-of-use assets 761 683 604 458 434
Operating lease right-of-use assets 331 406 471 496
Property and equipment, net, including finance lease right-of-use assets (including operating lease, right-of-use asset) 1,092 1,089 1,075 954 434
Long-term Activity Ratio
Net fixed asset turnover (including operating lease, right-of-use asset)1 13.20 12.74 10.57 11.62 23.99
Benchmarks
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2
AbbVie Inc. 10.24 9.57 7.46 10.06
Amgen Inc. 4.13 4.23 4.58 4.11
Bristol-Myers Squibb Co. 6.18 6.66 6.30 3.76
Danaher Corp. 6.35 6.10 5.30 5.84
Eli Lilly & Co. 2.63 2.93 2.63 2.66
Gilead Sciences Inc. 4.51 4.77 4.34 4.28
Johnson & Johnson 4.54 4.72 4.18 4.41
Merck & Co. Inc. 2.60 2.33 2.43 2.90
Moderna Inc. 8.62 12.78 0.52 0.00
Pfizer Inc. 5.20 4.59 2.74 3.39
Regeneron Pharmaceuticals Inc. 3.17 4.52 2.58 2.66
Thermo Fisher Scientific Inc. 4.13 3.98 4.82 4.69
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector
Pharmaceuticals, Biotechnology & Life Sciences 4.52 4.54 3.88 3.93
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry
Health Care 8.57 8.28 7.55 7.63

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Revenues ÷ Property and equipment, net, including finance lease right-of-use assets (including operating lease, right-of-use asset)
= 14,410 ÷ 1,092 = 13.20

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). IQVIA Holdings Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from 2020 to 2021 and from 2021 to 2022.

Total Asset Turnover

IQVIA Holdings Inc., total asset turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Revenues 14,410 13,874 11,359 11,088 10,412
Total assets 25,337 24,689 24,564 23,251 22,549
Long-term Activity Ratio
Total asset turnover1 0.57 0.56 0.46 0.48 0.46
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc. 0.42 0.38 0.30 0.37
Amgen Inc. 0.38 0.40 0.39 0.37
Bristol-Myers Squibb Co. 0.48 0.42 0.36 0.20
Danaher Corp. 0.37 0.35 0.29 0.29
Eli Lilly & Co. 0.58 0.58 0.53 0.57
Gilead Sciences Inc. 0.43 0.40 0.36 0.36
Johnson & Johnson 0.51 0.52 0.47 0.52
Merck & Co. Inc. 0.54 0.46 0.52 0.55
Moderna Inc. 0.71 0.72 0.03 0.00
Pfizer Inc. 0.51 0.45 0.27 0.31
Regeneron Pharmaceuticals Inc. 0.42 0.63 0.50 0.53
Thermo Fisher Scientific Inc. 0.46 0.41 0.47 0.44
Total Asset Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 0.48 0.45 0.38 0.39
Total Asset Turnover, Industry
Health Care 0.81 0.76 0.70 0.71

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Total asset turnover = Revenues ÷ Total assets
= 14,410 ÷ 25,337 = 0.57

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. IQVIA Holdings Inc. total asset turnover ratio improved from 2020 to 2021 and from 2021 to 2022.

Equity Turnover

IQVIA Holdings Inc., equity turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Revenues 14,410 13,874 11,359 11,088 10,412
Equity attributable to IQVIA Holdings Inc.’s stockholders 5,765 6,042 6,001 6,003 6,714
Long-term Activity Ratio
Equity turnover1 2.50 2.30 1.89 1.85 1.55
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc. 3.36 3.65 3.50
Amgen Inc. 6.77 3.63 2.58 2.30
Bristol-Myers Squibb Co. 1.49 1.29 1.12 0.51
Danaher Corp. 0.63 0.65 0.56 0.59
Eli Lilly & Co. 2.68 3.15 4.35 8.56
Gilead Sciences Inc. 1.27 1.28 1.34 0.98
Johnson & Johnson 1.24 1.27 1.31 1.38
Merck & Co. Inc. 1.29 1.28 1.90 1.81
Moderna Inc. 0.96 1.25 0.08 0.00
Pfizer Inc. 1.05 1.05 0.66 0.82
Regeneron Pharmaceuticals Inc. 0.54 0.86 0.77 0.71
Thermo Fisher Scientific Inc. 1.02 0.96 0.93 0.86
Equity Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 1.25 1.28 1.23 1.20
Equity Turnover, Industry
Health Care 2.17 2.10 2.07 2.07

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Equity turnover = Revenues ÷ Equity attributable to IQVIA Holdings Inc.’s stockholders
= 14,410 ÷ 5,765 = 2.50

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. IQVIA Holdings Inc. equity turnover ratio improved from 2020 to 2021 and from 2021 to 2022.